906673-85-6

Basic information

• Product Name: estradiol-17β-O-4-oxobutanoyl-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn
• Synonyms: estradiol-17β-O-4-oxobutanoyl-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn
• CAS NO: 906673-85-6
• Molecular Weight: 1073.21
• Mol File: 906673-85-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: estradiol-17β-O-4-oxobutanoyl-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn(CAS DataBase Reference)
• NIST Chemistry Reference: estradiol-17β-O-4-oxobutanoyl-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn(906673-85-6)
• EPA Substance Registry System: estradiol-17β-O-4-oxobutanoyl-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn(906673-85-6)

Safety Data

• Hazardous Substances Data: 906673-85-6(Hazardous Substances Data)

Upstream product

• 138108-43-7 Boc-Asp(OBzl)-Phe-OBzl 
• 2462-32-0 L-phenylalanine benzyl ester hydrochloride 
• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 50-28-2 estradiol 
• 906673-81-2 Boc-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn 
• 166953-02-2 Boc-Gly-Asp(OBzl)-Phe-OBzl 
• 7698-93-3 Estradiol-17-hemisuccinate 

Relevant articles and documents

Synthesis, evaluation and 3D QSAR analysis of novel estradiol-RGD octapeptide conjugates with oral anti-osteoporosis activity

To enhance the potency, reduce the side effects and improve oral property of estradiol in estrogen replacement therapy (ERT), 6 novel estradiol-RGD octapeptide conjugates have been prepared. In an ovariectomized mouse osteoporotic model, at an oral dosage

Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates

To improve the specificity and potency of estrogen replacement therapy therapeutics while also minimizing the side effects such as bone resorption and thickening of the uterine wall, a series of novel estrogen-derived conjugates estradiol-3-RGD, estradiol